Brevan Howard Capital Management’s ImmunityBio IBRX Stock Holding History

Brevan Howard Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$752K	Buy	85,857 +29,192	+52%	+$221K	0.01%	1225
2026 Q1	$435K	Buy	+56,665	New	+$388K	﹤0.01%	1388
2025 Q4	–	Sell	-143,221	Closed	-$352K	–	2030
2025 Q3	$352K	Sell	143,221 -5,490	-4%	-$14.1K	﹤0.01%	1478
2025 Q2	$393K	Sell	148,711 -197,233	-57%	-$530K	﹤0.01%	1454
2025 Q1	$1.04M	Buy	345,944 +246,187	+247%	+$746K	0.01%	483
2024 Q4	$255K	Buy	+99,757	New	+$416K	﹤0.01%	833
2024 Q3	–	Sell	-96,765	Closed	-$612K	–	1280
2024 Q2	$612K	Buy	+96,765	New	+$638K	0.01%	538

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's IBRX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its ImmunityBio (IBRX) stake by 52% in Q2 2026, buying an estimated $221K and bringing the position to 85,857 shares worth $752K. The position accounts for 0.01% of the portfolio, ranked #1225.

Brevan Howard Capital Management first reported a position in IBRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.04M in Q1 2025. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Brevan Howard Capital Management held 85,857 shares of ImmunityBio worth $752K as of Q2 2026.
Brevan Howard Capital Management bought 29,192 ImmunityBio shares in Q2 2026, an estimated $221K.
ImmunityBio made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1225 holding.
Brevan Howard Capital Management first reported a position in ImmunityBio in Q2 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's ImmunityBio position peaked at $1.04M in Q1 2025.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.